![John Miller](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
John Miller
Corporate Officer/Principal chez JAZZ PHARMACEUTICALS PLC
Postes actifs de John Miller
Sociétés | Poste | Début | Fin |
---|---|---|---|
JAZZ PHARMACEUTICALS PLC | Corporate Officer/Principal | 01/02/2015 | - |
Historique de carrière de John Miller
Anciens postes connus de John Miller
Sociétés | Poste | Début | Fin |
---|---|---|---|
ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/02/2012 | 01/08/2012 |
Enobia Pharma, Inc.
![]() Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Corporate Officer/Principal | 01/02/2011 | 01/02/2012 |
Formation de John Miller
University of Mississippi | Undergraduate Degree |
Questrom School of Business | Masters Business Admin |
Statistiques
Internationale
Etats-Unis | 4 |
Irlande | 2 |
Canada | 2 |
Opérationnelle
Corporate Officer/Principal | 3 |
Undergraduate Degree | 1 |
Masters Business Admin | 1 |
Sectorielle
Health Technology | 4 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
JAZZ PHARMACEUTICALS PLC | Health Technology |
Entreprise privées | 2 |
---|---|
Alexion Pharmaceuticals, Inc.
![]() Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Enobia Pharma, Inc.
![]() Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Health Technology |
- Bourse
- Insiders
- John Miller
- Expérience